What is the-wiseguy.com?
We, Bill-Bull and The-Wiseguy, are comfortably living our lives not bothered by any investor or boss, maybe just our wifes. Bill-Bull is a long-term value investor who bases his decisions solely on technical analysis (wiki) and The-Wiseguy is a swing-/daytrader (wiki) who has a more fundamental buying decision based on the news of the day (and because of that gets stuck with certain shares for a long time). In these posts we are expressing our thoughts about the stock we picked and occasionally about the world.
What is our goal?
Our moto: "There are tens of thousands of shares in the world but only a few are good enough to be wiseguys" (just click the motto) . We think a warning is in place, as a Dutch saying goes: "Resultaten uit het verleden bieden geen garantie voor de toekomst" meaning something like past returns do not guarantee the future. That is why we stay vigilant and so should you by reguarly reading our website. … We hope you have a good time and hereby apologize upfront for hurting or insulting anyone. That is never our intention.
….Stay home.....Stay safe....Stay informed….
.....................
You can find most of what you need in the menu on top of this page.In The Strategy we lay down the most important rules and explain what we think is required.
In The List we have an always updated watchlist, the list of what we call Wiseguys, the 50%/5y companies.
In The Performance. you can find out how we are doing this year and if we will reach our 40% annual profit.
And the most important pages are off course the messages we send out. All our buy and sell orders, the company bio and company stock charts, the TA and why we think you should buy or sell them (and at what moment in time). You can visit The Archive and you'll find the latest messages below:
Thanks for your time. If you liked what you are reading you can always buy me a coffee!
Update: December 31st 2019
It was a very exciting year but in the end we could have just bought an index tracker. That would have saved me a lot of transaction costs. Only my broker got rich in the end of the year.
Update: December 31st 2018
I made a few huge mistakes in the last month of the year. And all my profits vaporized in one month time. We call it learning money. Money you pay to learn from your mistakes.
What is SHOPIFY’S major task for the future?
One of my favorite stock for 2017 has to be Shopify (NYSE:SHOP). Since it’s IPO in may 2015 the stock has gone up 250% And rumor is that facebook and other big tech companies are looking to buy them. One of the biggest disadvantages for me is that they do…
Update: December 31st 2016
All in all a really nice return in the end. It’s been a rough ride but in the end payed of pretty nice.
Donald Trump America’s 45th President
Usually we do not discuss politics here but this time we will make an exception. America keeps amazing me. Every time they have to choose a president they never go for the save choice, that inspires me. After they had choosen the first black president in history, who performed exceptionally…
Estée Lauder – a steady climber in our longterm porto!
Since I have gotten my girlfriend involved in stock trading (and the fact that I believe that my porto will be a welcome addition to my pension later). We have tried to find some long term stocks that we both feel comfortable with. They say do not buy anything that…
GW’s Epidiolex results are worth mentioning
Whenever one of my biotech companies have good news. It almost always makes me smile. Yesterday it was GW. The shares of GW Pharmaceuticals (GWPH) are soaring on news that its cannabis-derived drug significantly diminished the seizure amount in children with a rare form of epilepsy in a phase-three trial. Epidiolex…
Nektar Announces First Patient Dosed in Phase 1/2 Clinical Study of NKTR-214
Maybe I’m a little late. But in december Nektar announced the following: Nektar Therapeutics (NASDAQ:NKTR) today announced that dosing has commenced in the Phase 1/2 clinical study evaluating the efficacy and safety of NKTR-214 in the treatment of solid tumors. NKTR-214 is a novel CD122-biased cytokine designed to preferentially activate…
Please keep in mind that the-wiseguy.com provides high-quality information. However detailed and excellent it might be. It is not financial advice.
Our lawyer would say: The-wiseguy.com tries to help you form an opinion on buying or selling a certain security. We will never tell you to do so. Also we may already hold a position in a certain stock or may never buy it at all. Our information does not take in account your investment objectives, particular needs or financial situation. Therefor we are not responsible for any gains or losses you may experience. Any security mentioned should be examined with ones own due diligence. Always consult a licensed and trustworthy profesional before making a financial decision.